Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells
Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells
复制标题
DOI：
10.1387/ijdb.103228jl
复制
发表时间：
2011-01-01
影响因子：
0.7
通讯作者：
Ruegg, Curzio
中科院分区：
文献类型：
--
作者：
Laurent, Julien;Touvrey, Cedric;Ruegg, Curzio
近年来，肿瘤相关炎症已成为促进肿瘤血管生成、肿瘤进展和转移形成的重要事件。骨髓源性细胞和炎症细胞通过提供分化为成熟内皮细胞的内皮祖细胞，并通过分泌促血管生成因子和重塑细胞外基质，通过旁分泌机制刺激血管生成，从而促进肿瘤血管生成。几种骨髓来源的骨髓细胞，包括单核细胞和巨噬细胞，近年来已经被几个实验室鉴定和表征。虽然这些细胞在促进肿瘤血管生成、肿瘤进展和转移方面的核心作用已被证实，但仍有许多问题有待解决，新的问题正在出现。这些包括它们的表型和功能之间的关系，促血管生成编程的机制，它们对抗血管生成治疗和转移的抵抗的贡献，以及它们作为血管生成和抗血管生成治疗的生物标志物的潜在临床应用。在这里，我们将回顾骨髓来源的髓系细胞的表型和功能方面，并讨论一些目前悬而未决的问题。
Cancer-related inflammation has emerged in recent years as a major event contributing to tumor angiogenesis, tumor progression and metastasis formation. Bone marrow-derived and inflammatory cells promote tumor angiogenesis by providing endothelial progenitor cells that differentiate into mature endothelial cells, and by secreting pro-angiogenic factors and remodeling the extracellular matrix to stimulate angiogenesis though paracrine mechanisms. Several bone marrow-derived myelonomocytic cells, including monocytes and macrophages, have been identified and characterized by several laboratories in recent years. While the central role of these cells in promoting tumor angiogenesis, tumor progression and metastasis is nowadays well established, many questions remain open and new ones are emerging. These include the relationship between their phenotype and function, the mechanisms of pro-angiogenic programming, their contribution to resistance to anti-angiogenic treatments and to metastasis and their potential clinical use as biomarkers of angiogenesis and anti-angiogenic therapies. Here, we will review phenotypical and functional aspects of bone marrow-derived myelonomocytic cells and discuss some of the current outstanding questions.